Business Context and Reporting Period
Company: Alcon, Inc. (Swiss corporation, majority-owned subsidiary of Nestlé S.A.)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three and nine months ended September 30, 2005
Filing Date: October 19, 2005
Business Overview: Global leader in ophthalmic products, operating through two segments: Alcon United States and Alcon International. Product categories include pharmaceuticals, surgical equipment/devices, and consumer eye care.
Key Financial Metrics
| Financial Metric (in millions) | 3 Months Ended Sept 30, 2005 | 3 Months Ended Sept 30, 2004 | 9 Months Ended Sept 30, 2005 | 9 Months Ended Sept 30, 2004 |
|---|---|---|---|---|
| Sales (Revenue) | $1,071.1 | $958.1 | $3,313.6 | $2,960.9 |
| Gross Profit | $824.7 | $709.5 | $2,490.9 | $2,148.3 |
| Gross Margin % | 77.0% | 74.1% | 75.2% | 72.6% |
| Operating Income | $367.9 | $277.0 | $1,114.5 | $901.3 |
| Net Earnings | $295.8 | $194.3 | $870.3 | $684.5 |
| Diluted EPS | $0.95 | $0.62 | $2.79 | $2.20 |
| Operating Cash Flow (9mo) | $1,073.1 | $862.5 | ||
| Cash & Equivalents (Sept 30, 2005) | ||||
| Total Debt (Sept 30, 2005) | $964.8 (Short-term: $890.5; Long-term: $74.3) |
Material Changes vs. Prior Period
- Revenue Growth: Global sales increased 11.8% (Q3) and 11.9% (9-month) year-over-year. Constant currency growth was 10.5% (Q3) and 9.7% (9-month), driven primarily by volume growth.
- Profitability: Net earnings surged 52.2% in Q3 and 27.1% in the 9-month period. Operating income rose 32.8% (Q3) and 23.7% (9-month).
- Margin Expansion: Gross margins improved due to reduced royalty expenses (following license restructuring), favorable product mix shifts to premium products, and production efficiencies.
- Segment Performance:
- Pharmaceuticals: Strong growth driven by Travatan (glaucoma), Vigamox (infection), and Ciprodex (otic). Generic competition impacted Ciloxan sales, offset by Vigamox and generic ciprofloxacin sales.
- Surgical: Growth fueled by AcrySof intraocular lenses (including the new ReSTOR lens) and cataract/vitreoretinal equipment. Refractive sales declined due to competitive pressure and lower procedure volumes.
- Consumer Eye Care: Artificial tears (Systane) grew significantly, offsetting declines in contact lens disinfectants due to price competition.
- Tax Rate: Effective tax rate decreased to 21.1% (Q3) and 22.7% (9-month) compared to 30.0% and 23.6% in 2004, respectively. The 2004 rate was artificially lowered by a one-time $57.6M tax benefit from amended returns.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects R&D expenses to increase in Q4 2005. The effective tax rate is expected to decrease by 3-4 percentage points in full-year 2005 compared to 2004, with further declines expected in 2006-2007.
- Capital Allocation: Significant cash outflows for shareholder returns: $302.0M in dividends and $292.7M in treasury share purchases during the first nine months of 2005.
- Legal Contingency (Material Risk): On May 6, 2005, a jury verdict found Alcon infringed two patents owned by Advanced Medical Optics Inc. (AMO) regarding the Infiniti Vision System. The verdict amount was $94.8 million. Alcon is appealing and believes the verdict is incorrect; no judgment has been entered. Potential loss could be up to the verdict amount.
- Accounting Changes: Alcon plans to adopt SFAS No. 123 (revised 2004) regarding share-based payment effective January 1, 2006. Proforma net earnings for the 9 months ended Sept 30, 2005, would have been $820.4M (vs. reported $870.3M) if the fair value method had been applied.
- Liquidity: Net cash position (cash minus total debt) increased to $147.7M. The company maintains $2.9B in credit facilities, including a $2.0B commercial paper facility guaranteed by Nestlé.
Investor Verification Checklist
- AMO Litigation Status: Monitor the appeal process regarding the $94.8M patent infringement verdict and potential impact on surgical equipment sales or future liabilities.
- ReSTOR Lens Adoption: Verify the commercial uptake of the AcrySof ReSTOR lens following the CMS reimbursement clarification in May 2005.
- Generic Competition: Assess the long-term impact of generic ciprofloxacin sales on the infection/inflammation portfolio as branded Ciloxan sales continue to decline.
- Tax Rate Sustainability: Confirm the projected reduction in the effective tax rate for the full year 2005 and subsequent years.
- Share Repurchase Program: Track remaining authorization for treasury share purchases (approx. 2.8M shares remaining under current authorizations as of Sept 30, 2005).